Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression

Breast Cancer Res Treat. 1991 Dec;20(1):11-7. doi: 10.1007/BF01833352.

Abstract

Plasma levels of platelet-derived growth factor (PDGF) were measured in 58 female patients with breast cancer and in 9 normal female control subjects by means of a specific radioimmunoassay. Levels in normal control subjects were all below the lower limits of detection by the assay (1.56 fmol/100 microliters plasma). Two of 17 (12%) patients with stage 2 breast cancer had detectable plasma levels. Among patients with Stage 4 breast cancer 13/41 (32%) had significantly elevated levels (greater than 2 times the lower limit of sensitivity of the assay). Patients with elevated PDGF levels had a significantly greater degree of metastatic involvement and significantly shorter survival. Apart from being a marker of aggressive high bulk breast cancer, PDGF may be involved in the acceleration of growth of some metastatic breast tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / blood*
  • Breast Neoplasms / blood*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Carcinoma, Intraductal, Noninfiltrating / blood*
  • Carcinoma, Intraductal, Noninfiltrating / mortality
  • Carcinoma, Intraductal, Noninfiltrating / pathology
  • Female
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Proteins / blood*
  • Platelet-Derived Growth Factor / analysis*
  • Prognosis
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins
  • Platelet-Derived Growth Factor